- Home
- SNDX vs FINV Comparison
SNDX vs FINV Comparison
Compare SNDX & FINV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- FINV
- Stock Information
- Founded
- SNDX 2005
- FINV 2007
- Country
- SNDX United States
- FINV China
- Employees
- SNDX N/A
- FINV N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- FINV Finance: Consumer Services
- Sector
- SNDX Health Care
- FINV Finance
- Exchange
- SNDX Nasdaq
- FINV Nasdaq
- Market Cap
- SNDX 1.3B
- FINV 1.5B
- IPO Year
- SNDX 2016
- FINV N/A
- Fundamental
- Price
- SNDX $19.91
- FINV $5.03
- Analyst Decision
- SNDX Strong Buy
- FINV Strong Buy
- Analyst Count
- SNDX 12
- FINV 2
- Target Price
- SNDX $36.92
- FINV $11.55
- AVG Volume (30 Days)
- SNDX 3.0M
- FINV 1.6M
- Earning Date
- SNDX 11-03-2025
- FINV 11-19-2025
- Dividend Yield
- SNDX N/A
- FINV 5.66%
- EPS Growth
- SNDX N/A
- FINV 27.76
- EPS
- SNDX N/A
- FINV 1.50
- Revenue
- SNDX $111,304,000.00
- FINV $1,969,555,571.00
- Revenue This Year
- SNDX $636.61
- FINV $11.56
- Revenue Next Year
- SNDX $114.95
- FINV $8.06
- P/E Ratio
- SNDX N/A
- FINV $3.50
- Revenue Growth
- SNDX 595.65
- FINV 8.81
- 52 Week Low
- SNDX $8.58
- FINV $4.70
- 52 Week High
- SNDX $20.08
- FINV $11.08
- Technical
- Relative Strength Index (RSI)
- SNDX 72.56
- FINV 33.10
- Support Level
- SNDX $16.75
- FINV $4.70
- Resistance Level
- SNDX $20.08
- FINV $6.03
- Average True Range (ATR)
- SNDX 1.23
- FINV 0.25
- MACD
- SNDX 0.40
- FINV -0.05
- Stochastic Oscillator
- SNDX 97.58
- FINV 19.21
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About FINV FinVolution Group
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.